Blood tests for Alzheimer's disease, which have received regulatory approval, could fundamentally change the way this disease is diagnosed and researched[1][2][3]. These tests measure specific proteins in the blood, particularly the phosphorylated form of tau protein (p-tau217) and amyloid-β, which are hallmarks of Alzheimer's disease[1][3]. According to research, the tests achieved high accuracy - the test with p-tau217 identified the disease with 96% to 98% accuracy and was able to detect the disease even in people without symptoms of dementia, in whom the disease could manifest itself in 20 years[1]. The new Lumipulse test, which measures the ratio of p-tau217 and amyloid-β, confirmed the presence of Alzheimer's pathology with 92% accuracy[3]. Blood tests could replace expensive and invasive examinations such as cerebrospinal fluid or PET scans of the brain[2][5]. As these tests move into clinical practice, clinicians will need to assess how best to use them in real-world patient care[1].